BPG is committed to discovery and dissemination of knowledge
Articles in Press
5/8/2022 7:06:51 AM | Browse: 53 | Download: 39
Publication Name World Journal of Clinical Cases
Manuscript ID 74945
Country/Territory South Korea
Category Gastroenterology and Hepatology
Manuscript Type Minireviews
Article Title Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea
Manuscript Source Invited Manuscript
All Author List Jun-Hyung Cho and So-Young Jin
Funding Agency and Grant Number
Funding Agency Grant Number
Soonchunhyang University Research Fund 10210061
Corresponding Author Jun-Hyung Cho, MD, PhD, Associate Professor, Digestive Disease Center, Soonchunhyang University Hospital, 59, Daesagwan-ro, Yongsan-gu, Seoul 04401, South Korea. chojhmd@naver.com
Key Words Helicobacter pylori; Treatment; Antibiotic resistance; China; Japan; South Korea
Core Tip Since 2000, the standard triple regimen containing clarithromycin (CAM) has been used as a legacy therapy to eradicate Helicobacter pylori (H. pylori). Resistance to CAM by H. pylori has increased to > 15% in East Asia. First-line eradication rates below 80% are strongly associated with CAM-resistant H. pylori strain emergence. H. pylori treatment guidelines in China, Japan, and South Korea were revised according to new data. In China, adding bismuth to H. pylori regimens was recommended as an empirical first-line treatment. In Japan, H. pylori treatment success increased when the potassium-competitive acid blocker (P-CAB) was introduced. In South Korea, tailored H. pylori eradication based on molecular testing for CAM resistance is used as the first-line treatment option. Dual therapy involving frequent administration of high-dose amoxicillin has shown good efficacy for H. pylori eradication in clinical trials. Furthermore, P-CABs, with their rapid and strong acid-suppressing activity, may contribute to successful H. pylori treatment in future.
Citation Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. World J Clin Cases 2022; In press
2022-01-13 04:18
Peer-Review Started
2022-01-13 04:20
To Make the First Decision
Return for Revision
2022-03-09 02:54
2022-03-11 09:04
Second Decision
2022-05-07 07:56
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2022-05-08 07:06
Articles in Press
2022-05-08 07:06
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Assistant Editor Assistant Editor
Science Editor Jia-Ping Yan
Reviewer Code 05143196, 01935510, and 05143196
Editorial Director
Journal Chief Editor
Company Chief Editor Lian-Sheng Ma
Language Editor
Production Editor
Responsible Production Editor
Responsible Science Editor
Proofing Editorial Director Jin-Lei Wang
Proofing Editor-in-Chief Lian-Sheng Ma
Manuscript File 74945_Auto_Edited.docx
Answering Reviewers 74945-Answering reviewers.pdf
Audio Core Tip 74945-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 74945-Conflict-of-interest statement.pdf
Copyright License Agreement 74945-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 74945-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate 74945-Language certificate.pdf
Peer-review Report 74945-Peer-review(s).pdf
Scientific Misconduct Check 74945-Bing-Yan JP-2.png
Scientific Editor Work List 74945-Scientific editor work list.pdf